CannabisNewsBreaks – Advanced Container Technologies Inc. (ACTX) Positioned in Rapidly Growing Market Estimated to Hit $172B in 2027

Advanced Container Technologies (OTC: ACTX) offers unique controlled environment farms called GrowPods. The company today announced a new report from KD Market Insights indicating that the market for controlled environment agriculture (“CEA”) is estimated to increase at a compound annual growth rate (“CAGR”) of 18.7% to reach $172 billion in 2027. The growth was attributed, in part, to an increase in world population, loss of agricultural land, as well as a strong demand for local foods. The report notes “remarkable advantages of CEA,” that include faster plant growth throughout the year, which allows for larger yields. “In a controlled environment, the plants have better health, which reduces the need for pesticides and other supplements. Owing to their good health, CEA grown produces are noticeably better in both size and quality then soil-grown crops,” the piece reads, further noting increased investment in CEA. “Major investments are being made by start-ups and established corporations in hydroponics, vertical farming, urban agriculture, and technology to optimize plant yield in controlled environments.”

To view the full press release, visit https://cnw.fm/vJBCM

About Advanced Container Technologies Inc.

Advanced Container Technologies is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer(R), that store and grind pharmaceuticals, herbs, teas and other solids or liquids. For more information, visit the company’s website at www.AdvancedContainerTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://cnw.fm/ACTX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — DOJ Requests Additional Time in Cannabis Consumption Sites Case

The U.S. Justice Department is seeking for more time from a federal court to answer a lawsuit over the legality of drug-use sites where individuals use illegal substances in a clinically approved environment. The institution at the center of this case, the Overdose Prevention Center, had initially allowed a request for prior delays in the case, but they did not agree to the latest scenario. They filed for an opposition motion instead.

This case has seen sustained delays in the past three years. The case was raised when the Department of Justice (under the Trump administration) denied a Philadelphia not-for-profit safehouse from initiating a harm-free facility.

In February, the Department of Justice was evaluating consumption sites that were supervised and was in discussion with the state as well as local leaders about worthy guardrails for the safehouses as an integral part of a holistic approach to the reduction of harm and the safety of the public.

The plaintiffs did not consent to this latest request by the justice department for more time and thus will be filing an opposition motion. In a statement, the safehouse said it believed there was progress when the justice department revealed that it had been evaluating its policies toward a controlled consumption service. The “appropriate guardrails” were meant to allow safehouses and other public health centers in the country to offer consumption services sans fear of criminal as well as civil enforcements from the federal department.

In Philly, four people overdose and die every day. A total of 1,276 fatal overdoses were documented last year alone, the highest on record. This is from a national statistic of drug overdose fatalities. The safehouse has been in litigation with the justice department since 2019 in an effort to flag off overdose prevention centers that have controlled drug consumption. Such centers provide critical strides in treatment, housing and the necessary social services to the drug users.

The Department of Justice now seeks to file an amendment counterclaim for Declaratory and Injunctive Relief by February 2023. This translates to another delay in the U.S. District Court in Pennsylvania a day after the court- approved Sunday deadline, much to the chagrin of the safehouse. This case has been pending in court for more than four years.

Because of the 2019–2021 litigation delay by the justice department, more than 3,000 people have overdosed in Philadelphia. Projecting into 2022, there is an expected spike in the deaths to 5,000 people.

While the facility in Philadelphia is entangled in litigations, New York opened a maiden harm education center late last year with officials posting positive life-saving reviews.

The Congressional Research Service pointed at a discrepancy saying the justice department actively protested the controlled consumption sites during Trump’s government, but Biden’s administration hasn’t sought to enforce the CSA against such sites. A report was issued within days after NIDA director Nora D. Volkow diplomatically endorsed the concept of authorizing the sites for safe consumption. She argued that scientific evidence demonstrated that these facilities can, in fact, prevent overdose fatalities.

Rahul Gupta, a drug czar at the White House, recently mentioned that the current administration would review the broader drug policy’s harm reduction suggestions, which include authorization of controlled consumption sites. He even suggested possible decriminalization.

The American Medical Association published a study in July stating that newly opened facilities in New York have reduced drug overdose fatalities and have redirected people from using drugs in public because there are facilities provided for this. These facilities also offer adjuvant services for drug users.

This case about safe consumption sites provides yet another front on which the fight to end marijuana prohibition is being fought. Another front is the state-level legalization movement which has, in a way, seen companies such as India Globalization Capital Inc. (NYSE American: IGC) to open shop and research cannabis-based medication.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Virginia Task Force Calls for Stricter Rules on Unregulated THC Products

Earlier this year, the General Assembly of Virginia established a task force to study the increase in unregulated delta-8 THC products in the state; the assembly has recommended tougher rules for businesses that sell these products.

Delta-8 THC is a psychoactive substance found in marijuana. Similar to delta-9 THC, which is found abundantly in marijuana, the compound produces a high when consumed, either through smoking or consuming an edible.

The state of Virginia legalized the recreational use of cannabis for individuals aged 21 and above in July 2021. Under the enacted law, individuals can legally possess up to an ounce of cannabis.

While legalization is a step forward in the movement to federally decriminalize cannabis, it has led to gaps in enforcement, with smoke shops and other stores selling a range of unregulated hemp-based products.

In November, the task force delivered a report recommending that businesses which sell delta-8 products apply for permits. Any business that fails to do so will have civil penalties imposed for flouting the rules.

The report also highlighted that inhaled and edible hemp products which were consumed, such as cannabis products, and sold without restriction were dangerous to individuals in the state, particularly children. In their recommendation, the task force concluded that ensuring that operating businesses had retail permits would help limit occurrence of marijuana-related pop-up shops.

While the report didn’t get into how hefty the fines imposed for businesses that violated the rules needed to be, the task force did emphasize that existing penalties weren’t weighty enough to ensure compliance. The report also recommends that an overhaul of how Virginia regulated all types of marijuana be conducted, suggesting that a strategy that was more coordinated be implemented. This would eliminate the need to have the responsibility be split among various agencies.

In addition to this, the task force also suggested that the total THC concentration of products be measured to determine their legality. This is mainly because most of the state’s marijuana laws are based on delta-9 THC measurements. The report explains that measuring total THC would also allow the state to distinguish between how it treated non-intoxicating vs. intoxicating products.

Furthermore, the task force also highlighted the need to implement stricter packaging rules in an effort to prevent minors from accidentally ingesting high THC doses. Attorney General Jason Miyares had warned earlier that the state would eliminate THC products packaged in a way that mimicked popular snack and candy brands.

These tighter regulations targeting products that were previously unregulated is likely to give the clients of companies such as REZYFi Inc. a more level playing field where all players abide by the same rules.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi, Inc. are available in the company’s newsroom at https://cnw.fm/REZY

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 2022 Calendar Year in Review

Lexaria Bioscience is a global innovator in drug delivery platforms whose patented DehydraTECH(TM) technology has demonstrated the ability to improve the bioavailability and increase the speed of onset of many drugs
In calendar 2022, the company achieved a number of milestones in various areas, including research programs, receipt of patents, and licensing agreements
Lexaria started and completed its fourth and most comprehensive hypertension study yet, investigating the capabilities of DehydraTECH-CBD, with the study showing that its formulation resulted in a sustained reduction in blood pressure over the study period (five weeks)
The company has also started investigating DehydraTECH-CBD as a potential therapeutic for the treatment of dementia and diabetes and is planning to begin another study on DehydraTECH-nicotine pouch performance
Over the course of the year, Lexaria was granted four new patents, and entered into separate licensing agreements with four new partners

In his concluding remarks in this year’s letter to shareholders published January, Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka underlined that “Management of [the company] feels we are on track, on schedule, and on budget to deliver what we hope and expect will be great results in 2022” (https://cnw.fm/gfw3L). Since then, the company has achieved crucial milestones that can well be described as “great results,” and rightly so. These milestones are centered around Lexaria’s patented DehydraTECH(TM) drug delivery technology.

DehydraTECH can be applied to many drugs and fat-soluble active pharmaceutical ingredients (“APIs”), with the resultant formulation boasting better speed of onset, bioavailability, and brain absorption. So far, Lexaria has evidenced, through pharmacokinetic (“PK”) studies, that its technology delivers higher quantities of cannabidiol (“CBD”), oral nicotine, and antiviral drugs into the bloodstream in less time, properties that are technically known as increased bioavailability.

For Lexaria, however, the end goal does not only lie in uncovering DehydraTECH’s ability to improve the bioavailability of various APIs. Instead, the company is keen on establishing whether DehydraTECH can be applied broadly within the pharmaceutical industry. And calendar 2022 has brought the company closer to realizing this goal, with the company initiating a slew of research programs, many of which it has already completed. Moreover, its intellectual property (“IP”) portfolio has received additional patent protection in different jurisdictions around the world. Lexaria has also entered into multiple manufacturing and/or licensing agreements with global partners.

Research Programs

DehydraTECH-Processed PDE5 Inhibitor

Lexaria kicked the year off with an announcement of ground-breaking findings in an animal study evaluating DehydraTECH-processed sildenafil, a phosphodiesterase (“PDE5”) inhibitor used in the management of erectile dysfunction. The study, whose results were announced February 2, showed that the DehydraTECH formulation delivered more sildenafil (roughly 70% more drug) and at a faster rate (about 25% faster) than the concentration-matched, generic control formulation (https://cnw.fm/SnLRR).

DehydraTECH-Processed CBD

In 2022, much like in 2021, Lexaria’s biggest area of investigation was CBD – or, more specifically, DehydraTECH-processed CBD. The company expanded the scope of its research to include not only investigations on hypertension or high blood pressure, a condition on which it had completed two human studies (HYPER-H21-1 and HYPER-H21-2) the year prior, but also diabetes, seizures, and dementia.

Building on the HYPER-H21-1 study, a 24-person study that evidenced a rapid and sustained drop in blood pressure, and HYPER-H21-2, which showed that DehydraTECH-CBD caused a 23% average reduction in overnight blood pressure and reduced arterial stiffness, Lexaria also released the findings of its 16-person HYPER-H21-3 study in April this year. This third study evidenced that the pulmonary artery systolic pressure was attenuated by about 5 mmHg or 41% overall in male participants (https://cnw.fm/w5iOL).

The positive findings from the HYPER-H21-3 study set the stage for the commencement of the fourth human clinical study (“HCS”), HYPER-H21-4, the most comprehensive study Lexaria has ever undertaken, that same month (https://cnw.fm/IlHTK). A 66-person randomized, double-blinded, placebo-controlled, cross-over study, HYPER-H21-4 was designed as a multi-week study whose dosing was completed in July with no serious adverse events reported. That was a vital outcome given that the main objective of most FDA-registered Phase I studies is to prove safety and tolerability.

This news was a precursor to even more positive news reported in late October when Lexaria announced that HYPER-H21-4 “may be the world’s first study to evidence a sustained drop in blood pressure (“BP”) in normally active hypertensive patients following multiple weeks of oral CBD therapy, using Lexaria’s patented DehydraTECH-CBD capsule formulation.”

The study showed a significant BP reduction by 2.5 weeks, with this attenuation sustained over the entire five weeks of dosing. Moreover, Lexaria also observed that the decreases in BP were similar in persons receiving treatment with standard-of-care BP medication as in persons who were not undergoing any current treatment, suggesting DehydraTECH-CBD’s potential abilities to offer additive BP reduction benefits above and beyond the therapeutic improvements of standard BP medication. This can have important regulatory implications.

“That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,” Chris Bunka commented. “DehydraTECH also demonstrated excellent safety and tolerability results and no adverse changes in liver enzymes throughout the study. Indeed, of the handful of minor, non-serious adverse events reported, there were nearly as many reported by those patients receiving placebo as those who received DehydraTECH-CBD.”

HYPER-H21-4 was designed to enhance Lexaria’s probability of success with its expected Investigational New Drug (“IND”) application to seek the US Food and Drug Administration (“FDA”) approval to begin registered clinical testing. Against the backdrop of the findings from this study, and having already received positive feedback from a pre-IND meeting with the FDA, according to an August press release (https://cnw.fm/lZ2Eo), Lexaria is on track to file the full IND application in 2023. (Following the pre-IND meeting, the FDA confirmed its support for an abbreviated approval pathway in line with section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.)

Meanwhile, in a separate three-part animal study that kicked off in March that aimed to assess the effectiveness of DehydraTECH-CBD in reducing seizure activity compared to the FDA-approved seizure medication Epidiolex (https://cnw.fm/hHsfv), Lexaria evidenced that DehydraTECH-CBD can be more efficacious at lower doses than Epidiolex. Additionally, the company observed that DehydraTECH-CBD can act more rapidly than Epidiolex. According to Lexaria, work is ongoing to complete the third and final part of the study that intends to establish the dose required to achieve seizure inhibition in 50% of the animals tested or ED50 (https://cnw.fm/cKuVx).

In addition to the hypertension and seizure studies, Lexaria recently commenced separate investigations on the potential therapeutic use of DehydraTECH-CBD in both diabetes and dementia. Dubbed DIAB-A22-1, the study investigating DehydraTECH-CBD’s potential utility in the treatment of diabetes kicked off on November 8 (https://cnw.fm/LV8q6), while DEM-A22-1, the study on the potential use of DehydraTECH-CBD in dementia, begun a couple of days later on November 10 (https://cnw.fm/sZQLD).

DehydraTECH-Processed Nicotine

Calendar 2022 also marked the year when Lexaria began expanding its research on nicotine to include human subjects. Having resolved the manufacturing and logistics challenges that had previously pushed back the commencement time as well as having received Independent Review Board (“IRB”) approval for the planned human oral nicotine study, NIC-H22-1, Lexaria expects to begin dosing in December 2022 (https://cnw.fm/m0Zuy).

A 36-person human PK, randomized, double-blinded, cross-over-study carried out in current cigarette smokers, NIC-H22-1 will see each participant receiving only one brand of oral nicotine pouch on each of the three visits to the laboratory over a period of weeks. Upon administration, each person will undergo both subjective and objective evaluations, with vital signs such as respiratory rate, heart rate, blood pressure, and temperature also collected. Overall, the study is specifically designed to compare the performance of Lexaria’s DehydraTECH-nicotine pouch to On!’s (a pouch brand manufactured by Altria) and Zyn’s (the world’s leading nicotine pouch product manufactured by Swedish Match).

Competition in the nicotine pouch category is heating up, with PMI have just completed its US$16 billion acquisition of Swedish Match.

Previously, Lexaria had demonstrated in animal study NIC-A21-1 that oral nicotine pouches processed using DehydraTECH were 10 to 20 times faster in reaching peak delivery of nicotine to the bloodstream than controls.

Patents

In 2022, Lexaria continued to strengthen its intellectual property portfolio, receiving four new patents as described below:

In March, Australia granted Lexaria a patent entitled “Compositions Infused with Nicotine Compounds and Methods to Use Thereof” that covers most oral forms of nicotine, including sprays, gums, pouches, capsules, lozenges, tablets, and pills. The patent also covers various forms of nicotine, including free base nicotine, polymer resins of nicotine, nicotine salts, and other forms of nicotine complexes (https://cnw.fm/jYD7f).
In April, the United States Patents and Trademark Office (“USPTO”) granted Lexaria its first-ever patent for using DehydraTECH technology to enhance the delivery of antiviral drugs (https://cnw.fm/T8LzG).
In July, Lexaria received its fourth patent granted in Japan, entitled “Lipophilic Active Agent Infused Compositions with Reduced Food Effect,” which acknowledges the ability of DehydraTECH to deliver APIs more effectively regardless of the presence of foods within the gastrointestinal
system (https://cnw.fm/XFvd4).
In August Lexaria received a new patent in Mexico that covers multiple claims, including but not limited to the treatment of hypertension, neurological diseases, diabetes, hepatic diseases, and more (https://cnw.fm/Pw52T).

With the receipt of the four patents in 2022, Lexaria now has 27 worldwide patents granted, with about 50 more patents pending worldwide. The company believes that should the remaining patent applications become granted patents, its ability to generate meaningful license revenue from its IP may increase from multiple other countries and regions outside of the United States. And if this year’s licensing agreements are anything to go by, Lexaria is progressively inching closer to this goal, one partner at a time.

Licensing Agreements

Generally, the company’s granted patents help to buttress a part of the company’s business plan, which according to its latest annual report, is to “encourage new and existing participants to license and utilize DehydraTECH to enable enhanced performance of their products” (https://cnw.fm/NhHJh). To that end, this calendar year saw the company onboard new partners who have licensed the DehydraTECH technology for use in their respective markets. Anchored in licensing agreements announced in June, the licenses include:

A European and United Kingdom DehydraTECH license for medical cannabis applications from wholly owned subsidiary Lexaria Pharmaceutical Corp. to Valcon Medical A/S, a European contract manufacturing organization (“CMO”) that manufactures medical cannabis extracts for the European Union (“EU”) and the UK (https://cnw.fm/e58yq)
An exclusive commercial licensing agreement granted to Premier Wellness Science Co. Ltd. for the Japanese non-pharmaceutical market for the use of DehydraTECH with CBD and hemp ingredients in oral liquid and non-liquid products, topical, hair, lip-care, and cosmetics products (https://cnw.fm/SVWi8)
A five-year, non-exclusive DehydraTECH license to AnodGen Bioceuticals of Ireland, a CMO, for the manufacturing and distribution of DehydraTECH-processed cannabinoid API powders within Europe, Australia, and New Zealand (https://cnw.fm/enV29)
Two agreements – a manufacturing operating agreement and a commercial license agreement – with Atlanta-based BevNology LLC. (https://cnw.fm/XO2UL)

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Federal Health Secretary Provides Update on Cannabis Scheduling Review

Secretary Xavier Becerra of the U.S. Department of Health and Human Services recently revealed during an event on overdose prevention that the agency was focused on completing a review on federal marijuana scheduling, as was recently directed by President Joseph Biden.

President Biden ordered that a scheduling review be carried out by the department following his issuance of marijuana pardons, which saw thousands of individuals convicted of simple marijuana possession under federal law being released.

The health secretary has thus far raised the issue with the head of the FDA, Dr. Robert M. Califf. The department head added that the FDA was committed to supporting evidence-based policies for cannabis, noting that the science-focused approach also applied to policy decisions on other drugs.

When asked about drug decriminalization efforts, Becerra noted that while it wasn’t in the department’s jurisdiction to make policy decisions on such matters, the department would base its guidance to the federal government on both evidence as well as science. He then added that the main focus when it came to drug policy needed to be on keeping individuals alive and allowing them to thrive. Becerra has in the past supported marijuana reform as an attorney general of California and even before, as a Congressman.

Senator Tammy Baldwin, who was also present at the event, revealed that she was in favor of cannabis decriminalization. Baldwin, who has co-championed a number of reforms, also highlighted the conflict between state law and federal law when it came to drug policies.

With regard to Biden’s scheduling order, Rahul Gupta, the White House Drug Czar, stated that the move was historic and highlighted that marijuana possessed various medical benefits.

The Department of Justice is also conducting a separate scheduling review as directed by Biden; its review could cause marijuana to be reclassified in a lower schedule or even be scraped from its current classification altogether. Marijuana’s removal from its current schedule would effectively legalize it under federal law. This move is supported by the majority of Americans, with a series of polls showing that most are in favor of Biden’s pardon action and do not think cannabis qualifies to be classified as a Schedule I federal drug.

At the moment, however, the drug will remain classified as a Schedule I substance under the Controlled Substances Act.

In related news, the president commended a move by Governor Kate Brown of Oregon to grant cannabis pardons to tens of thousands of individuals, noting that other states needed to follow suit.

The entire cannabis industry, including entities such as Flora Growth Corp. (NASDAQ: FLGC), will be following the scheduling review process closely since the policy recommendations made could have far-reaching implications for the future of the industry.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — The Unique Benefits of Marijuana to the Bipolar Community

Cannabis has proved to have an effect in improving cognitive functions all the while helping to reduce risky decision-making, new research has found. Currently, more than 40 million people suffer from bipolar disorders globally. Bipolar disorder, or manic depression, has catastrophic effects on one’s daily endeavors including relationships and work processes. In this data, a good number of people suffer mild or extreme aspects of bipolar disorder but are unaware of the diagnosis.

Bipolar disorder is categorized in two main sets: bipolar I, where one exhibits manic episodes lasting a week or so, such an individual may need hospitalization; and bipolar II, where a patient presents with manic depressive episodes and elevated mood swings that could agitate the patient. Those agitating episodes could lead to high energy in the patients. The patient could also exhibit a cyclothymic disorder where they present with cyclical rapid high-low emotions or mood swings. These mood swings alternate from high-energy excitedness to a depressive dip in a small span of time.

Conventional medicine has been of help in alleviating the symptoms. However, many patients under conventional psychotic drugs do not seem to find much relief because, for one, the drugs take a long time before the effects kick in, and these drugs come with a myriad of side effects. Cannabis has come in handy as a natural and safe alternative for bipolar patients.

In a new study, researchers presented some findings in the Neuroscience 2022 conference seeking to understand how cannabis affects the cognitive and goal-directed behaviors among people with bipolar disorder. This study revealed that marijuana may have uniquely beneficial effects for those consuming it chronically. Researchers said that marijuana was effective specifically in improving cognitive function while also reducing risky decision-making. The researchers also deduced that cannabis reduces the dopaminergic activity in the brain to suppress bipolar symptoms.

There have been other older studies that produced similar findings. In a 2018 clinical trial, researchers discovered that consumption of cannabis improved the clinical symptoms of bipolar disorder. This was the first-ever clinical trial to be conducted with the aim of understanding how marijuana affects neuropsychological performance.

Researchers from Harvard Medical School, in conjunction with other scientists, studied the impact of cannabis on cognitive function and mood among bipolar patients. They found that marijuana consumption led to reduced scores for depression and anger, among other emotional expressions, and also led to heightened vigor in the same patients.

In 2020, a review by researchers at New Mexico University found that cannabis was useful in treating depression symptoms. Antidepressant drugs have had negative effects on bipolar patients, but cannabis checks for safety, effectiveness and natural remedy for the treatment of bipolar disorder. There has been a positive impact on the neuroendocrine, neurotransmission and neuroimmune systems when the endocannabinoid system is boosted with the use of cannabinoid-based products. These are the systems adversely affected by bipolar disorder, resulting in depression and other mood disorders.

A 2006 Montreal study also discovered that increasing endocannabinoids produced by the brain increases effectiveness in one’s mood. According to the lead researcher, this was the first time a drug that increased cannabinoids in the brain also improved one’s mood. Another 2020 report from BMC Psychiatry showed that the whole cannabis plant and other plant-based cannabinoids do improve mood and sleep but also reduce anxiety and psychotic disorders.

The research body on cannabis for bipolar disorders is in its infancy, but the studies do show promise. With expanded research and clinical trials, bipolar patients will have a plethora of options outside of the conventional drugs that pharmaceutical giants are availing on the market.

As the therapeutic potential of this plant is confirmed for different medical indication, there could be a spike in the number of people looking for cannabis-growing equipment from manufacturers such as Advanced Container Technologies Inc. (OTC: ACTX) in a bid to have access to this life-changing medication cost-effectively.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

REZYFi, Inc. to Benefit as Marijuana Sales Projected to Hit $53 Billion by 2026

Marijuana sales are projected to hit $33 billion in 2022, up from $3 billion in 2015, and are on track to hit $53 billion by 2026
REZYFi, a growth mortgage origination and specialized financing company, with target markets including the legalized cannabis industry, is set to be one of the key beneficiaries in this anticipated growth
With the ongoing conversation around marijuana, along with the bipartisan support for its legalization, the company is optimistic that the demand for its products and services will see a spike as time progresses
REZYFi still believes that financing options for cannabis-related firms will continue to be scarce, despite progress in marijuana legalization, presenting an opportunity for the company

Back in 2017, marijuana sales were valued at $9 billion. By the end of 2022, sales are projected to hit $33 billion, posting a 20% growth. The sector is also on track to hit $53 billion in sales by 2026 (https://cnw.fm/4Lqud). REZYFi, a growth mortgage origination and specialized financing company based in the United States, is set to be one of the key beneficiaries of this anticipated growth. Given its focus on licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, along with companies and individual homeowners seeking a variety of real estate-related and additional mortgage-based financing, the growth of the marijuana sector is bound to come with expanded market opportunities for the company.

For the longest time, cannabis-related businesses and companies have struggled to obtain financing from traditional banks. Federal law has forced traditional banks to shun such businesses, given that marijuana use is criminalized. However, with the ongoing conversation around marijuana, along with the bipartisan support for its legalization, REZYFi is optimistic that the demand for its products and services will see a spike as time progresses.

“REZYFi believes the demand for innovative financing offerings by players in the cannabis market will continue to grow as more geographic markets legalize recreational and medical cannabis usage, a belief that has fueled its expansion within the United States,” notes a recent article (https://cnw.fm/jbSgH).

Despite progress in the legalization of marijuana, REZYFi still believes that financing options for cannabis-related firms will continue to be scarce, as traditional banks are slow to adapt to the changing environment. As a result, it reckons that these entities will continue to experience difficulties obtaining financing from these traditional sources, which, while a downside on the businesses’ part, is an opportunity for REZYFi.

So far, REZYFi is licensed in 36 states, with plans to expand into additional jurisdictions, hopefully within the coming year. With President Biden set to sign the first official stand-alone piece of marijuana legislation this month, the company anticipates a bump in demand for its offerings. In addition, the proliferating bipartisan marijuana legislation, coupled with the growing public support, highlights encouraging long-term momentum for the entire marijuana industry, which will be integral to REZYFi’s growth.

For more information, visit the company’s website at www.REZYFi.com.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://cnw.fm/REZY

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – ECGI Holdings Inc. (ECGI) Issues Update on Strategic Vision

ECGI Holdings (OTC: ECGI), D/B/A Elite Cannabis Group Incorporated, a Nevada-based portfolio company pivoting into the legal cannabis and cannabinoid marketplace, today provided an update to current and prospective shareholders. According to the update, the company is targeting a leadership role in product manufacturing and wholesale distribution in the legal cannabis marketplace in California. The company believes it has a built-in edge in targeting this niche, which offers a value proposition to small and medium sized grow operations and retailers. “The industry has effectively over-verticalized and there’s rampant inefficiency that drives value destruction for smaller producers and for the whole retail side of the equation,” said Danny Wong, CEO of ECGI. “We are now well into the process on the strategic side, and we believe ECGI can grow into something akin to the Costco of the California cannabis market.”

To view the full press release, visit https://cnw.fm/oxUHW

About ECGI Holdings Inc.

ECGI Holdings, which plans to operate as Elite Cannabis Group, is reorganizing as an acquisition-oriented corporation with California-based targets including undercapitalized and distressed licensed cannabis assets, properties zoned for cannabis cultivation and processing, and cannabis companies operating in market sectors with nationwide expansion possibilities. For additional information, please contact the company at info@ecgiholdings.com.

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Colorado Regulators Allow Medical Cannabis to Be Recategorized as Recreational Marijuana

Last week, the Marijuana Enforcement Division in the state of Colorado announced that cannabis grown under a medical cultivation permit could be recategorized as retail products and sold in adult-use shops. The division, which is tasked with the licensing and regulation of medical and retail cannabis industries in the state, also announced new safety protections for employees involved in the manufacture of marijuana. Workers who take part in a range of manufacturing tasks will now be required to wear goggles and masks as well as respirators.

Other announcements included the news that the eligibility period for would-be social equity licensees would also be extended from one to two years, which would afford equity applicants more time to navigate the licensing process once they were determined to be eligible.

In a news release, the division also announced that a report on intoxicating hemp products would be presented to the state legislature on Jan. 1, 2023. Intoxicating hemp products include delta-9 THC derived from hemp, which is a potent cannabinoid that induces a high when consumed. The agency also announced that business owners could also easily shift marijuana from one license type to another, which would significantly simplify business operations.

Currently, data from the state shows that it has 789 licensed cultivators of recreational cannabis and 431 licensed cultivators of medical cannabis, with some businesses holding both license types. With regard to retail outlets, the state of Colorado has 669 licensed recreational shops and 399 licensed medical dispensaries.

Observers of the burgeoning cannabis industry estimate that the total number of physical stores surpasses 700.

Licensees that hold both adult-use and medical permits to cultivate marijuana will also be allowed to change between medical cannabis to retail, on the condition that both permits have one or more common owners. This is stipulated in a measure that was recently signed by Governor Jared Polis.

The Marijuana Enforcement Division also announced that beginning Jan. 1, 2024, marijuana flower and pre-rolls sold in the state need to be labeled with a use-by date. These products will also need to be packaged with proper instructions on how they should be stored.

In addition to this, licensees have been ordered to carry out testing on shelf stability to determine appropriate sell-by dates for their products. Marijuana that isn’t tested will have a nine-month shelf life. However, the agency notes that marijuana can still be sold even after it passes its use-by date, as long as the buyer is aware of it.

Many companies such as India Globalization Capital Inc. (NYSE American: IGC) are going a step further to develop therapeutic formulations based on cannabis compounds so that these products secure FDA approval and are available for prescription.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — NJ Regulators OK Cannabis Consumption Lounge Rules

Marijuana industry regulators in the state of New Jersey have approved regulations for “public marijuana consumption areas,” taking the state a step closer to permitting social consumption for patients and adults. Shops selling marijuana opened their doors this April, but advocates are insisting on the necessity of establishing regulations that would accord users more spaces for lawful cannabis consumption.

Recently, New Jersey’s Cannabis Regulatory Commission (CCR) moved close to achieving this when they approved requirements to oversee the consumption venues as well as fees that businesses which operate those sites have to pay.

Currently Cannabis is accessible to everyone 21 years of age or older who wishes to partake of the substance responsibly, in a safe and legal area. When the above is regulated well, cannabis consumption kiosks could boost the industry and also give consumers a variety of choices on consumption sites, said CRC chair Dianna Houenou.

Under the draft rules, foods cannot be sold at the consumption site, though people may be allowed to bring food in or order its delivery to the site. Alcoholic beverages or tobacco cannot be consumed or sold within the marijuana-consumption premises. The site can be either indoors or outdoors, though if outdoors it must be enclosed. The standard fees for licenses and application fees have been proposed to stand at $1,000.

One regulatory commissioner expressed joy at the approval because it paves the way for safe spaces for patients as well as consumers to use cannabis uninhibited. These rules will be published in New Jersey’s register prior to being finalized. This is to give the public 60 days to comment on the rules. The CRC also gave the nod to 113 conditional marijuana licenses, eight yearly licenses and half a dozen conversions from conditional licenses to annual.

The social consumption regulations in New Jersey come just a few days after regulators declared the recipients of the Nevada’s first marijuana lounge licenses.

Alaska was the first to enact rules providing for on-site consumption at dispensaries; the rules were enacted in 2019. Colorado was next in line with legislation passed that legalized marijuana “tasting rooms” as well as “marijuana hospitality sites” where adults were free to use cannabis.

In New York, social-consumption locations are included in the recently enacted cannabis legalization law. The New Jersey governor said that the state needs to reconsider its current ban of marijuana home cultivation for individual use. This conversation should come later on, post maturity of the recreational market, he added.

In October 2022, the Assembly in New Jersey approved a bill that allowed licensed cannabis companies to deduct some expenses from their state-level tax returns as a partial fix because this industry continues to be blocked from claiming federal tax deductions due to an IRS code 280E.

Even though the market for adult-use cannabis is still growing, it has proven profitable. New Jersey posted $80 million in cannabis sales during the first two and a half months since inception in April.

NJ senate president, Nicholas Scutari, filed a bill that would also authorize the state’s governor to transact with other jurisdictions that have legalized marijuana for interstate marijuana commerce. The agreements may only be implemented if federal laws change or if the DOJ issues guidelines permitting it. Scutari also filed legislation to legalize magic mushrooms, or psilocybin. The proposal has clauses allowing individuals to grow this psychedelic at their homes.

As enterprises such as REZYFi Inc. step up their support to the cannabis industry, the country is likely to see more businesses opening in the space despite the lack of access to funding from mainstream banks.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi, Inc. are available in the company’s newsroom at https://cnw.fm/REZY

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.